Tuspetinib / Venetoclax / Azacitidine triplet

May 13, 2026 — Aptose Biosciences, Inc. (TSX: APS; OTC: APTOF) reported Q1 2026 financial results (quarter ended March 31, 2026) and provided a corporate update focused on its AML program tuspetinib and a pending acquisition by Hanmi Pharmaceutical.

Key updates: (1) The previously announced plan of arrangement with Hanmi Pharmaceutical Co., Ltd. and subsidiary HS North America Ltd. was delayed due to ongoing Korean regulatory approvals; Aptose said the parties still target closing in May and do not expect reviews to prevent closing. Under the agreement, eligible shareholders would receive C$2.41 per share (28% premium to the 30-day VWAP of C$1.88 at signing). (2) Updated Phase 1/2 TUSCANY trial data (tuspetinib + venetoclax + azacitidine frontline triplet for newly diagnosed AML ineligible for induction) was selected for an oral presentation at EHA 2026 (June 14, 2026), including updates across 80/120 mg and new 160 mg tuspetinib cohorts with safety, remission, MRD, and follow-up data. (3) Aptose terminated its luxeptinib (CG-806) license and returned rights to CGI Invites.

Financials: Q1 2026 net loss was $7.6M (vs $5.5M Q1 2025); R&D expenses rose to $3.6M (vs $2.4M), driven by higher tuspetinib program costs. Cash and restricted cash were $4.1M; Aptose stated it lacks sufficient cash to fund operations and is relying on advances from Hanmi while pursuing cost reductions.